

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/067976-2025>

Contract

NHS Genomic Medicine Service - Most Suitable Provider Process

NHS England

F03: Contract award notice

Notice identifier: 2025/S 000-067976

Procurement identifier (OCID): ocds-h6vhtk-0565e9

Published 23 October 2025, 5:00pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

7&8 Wellington Place

Leeds

LS1 4AP

Contact

Anna Salt

Email

anna.salt@nhs.net

Country

United Kingdom

Region code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Genomic Medicine Service - Most Suitable Provider Process

Reference number

C368833

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic

Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.

Pursuant to the NHS GMS contracts, provider are to provide the following functions:

- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital

II.1.6) Information about lots

This contract is divided into lots: Yes

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £5,175,000,000

II.2) Description

II.2.1) Title

Lot 1 – NHS North-West GMS

Lot No

1

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKD - North West (England)

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2 – NHS North-East and Yorkshire GMS

Lot No

2

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKC - North East (England)

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 3 – NHS Central and South GMS

Lot No

3

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKG - West Midlands (England)

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;

- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 4 – NHS East GMS

Lot No

4

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKH - East of England

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 5 – NHS South-West GMS

Lot No

5

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKK - South West (England)

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;

- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 6 – NHS North Thames GMS

Lot No

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKI - London

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria / Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 7 – NHS South-East GMS

Lot No

7

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKJ - South East (England)

II.2.4) Description of the procurement

Pursuant to the NHS GMS contracts, providers are to provide the following functions:

- * Organisational leadership, governance and partnership arrangements;
- * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- * Laboratory operating model;
- * Clinical function: cancer genomics;
- * Clinical function: rare disease;
- * Clinical function: population health;
- * Promotion of and supporting and leading where relevant science, research and / or innovation;
- * Transformation and Service Improvement;
- * People – workforce, education and training; and
- * Data and digital

The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which,

under PSR, constitutes a new service.

The approximate lifetime value of the contract for all Lots is £5,175,000,000.

The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).

Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

II.2.5) Award criteria

Cost criterion - Name: Most suitable provider process with regard to the key Criteria /

Weighting: 100

II.2.11) Information about options

Options: Yes

Description of options

Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: [2025/S 000-042969](#)

Section V. Award of contract

Lot No

1

Title

Lot 1 - NHS North-West GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Manchester University NHS Foundation Trust

Manchester

Country

United Kingdom

NUTS code

- UKD3 - Greater Manchester

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

2

Title

Lot 2 - NHS North-East and Yorkshire GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle

Country

United Kingdom

NUTS code

- UKC2 - Northumberland and Tyne and Wear

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

3

Title

Lot 3 NHS Central and South GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Birmingham Women's and Children's NHS Foundation Trust

Birmingham

Country

United Kingdom

NUTS code

- UKG3 - West Midlands

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

Title

Lot 4 NHS East GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Cambridge University Hospitals NHS Foundation Trust

Cambridge

Country

United Kingdom

NUTS code

- UKH1 - East Anglia

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

5

Title

Lot 5 NHS South-West GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

North Bristol NHS Trust

Bristol

Country

United Kingdom

NUTS code

- UKK1 - Gloucestershire, Wiltshire and Bristol/Bath area

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

6

Title

Lot 6 NHS North Thames GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Great Ormond Street Hospital for Children NHS Foundation Trust

London

Country

United Kingdom

NUTS code

- UKI3 - Inner London – West

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section V. Award of contract

Lot No

7

Title

Lot 7 NHS South-East GMS

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

21 October 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Guy's and St Thomas' NHS Foundation Trust

London

Country

United Kingdom

NUTS code

- UKI3 - Inner London – West

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £5,175,000,000

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime (PSR) intention to award notice. This intention to award notice is subject to Regulation 10(7) of the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Written representations should be sent to england.genomics@nhs.net, ensuring the following details are referenced:

Project reference: C368833

Project title: NHS Genomic Medicine Service - Most Suitable Provider process

This decision has been made as per NHS England governance processes, by the Commercial Executive Group on 14th October 2025 and the National Commissioning Group on 21st October 2025. No conflicts of Interest were identified amongst decision-makers.

Each of the 5 key criteria were balanced with equal priority and considered on this basis and consideration was given to the basic selection criteria. Following provider assessments, it was agreed that the providers are the only providers capable of meeting the service specifications and requirements of the NHS GMS in full.

Additional CPV codes include:

85145000-7 (Services provided by medical laboratories),

85148000-8 (Medical analysis services)

85111810-1 (Blood analysis services)

85121200-5 (Medical specialist services)

85140000-2 (Miscellaneous health services)

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>